Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Inhibiton Therapeutics' Researcher to Present at American Association for Cancer Research Annual Meeting
April 22nd, 2008
Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced that the principal researcher for its ICA-1 compound, Dr. Mildred Acevede-Duncan, will present an abstract of the ICA-1 compound at the American Association for Cancer Research ("AACR") Annual Meeting in San Diego, California on April 14, 2008. The Company's abstract has been scheduled for presentation in a Poster Session at the 2008 AACR Annual Meeting in San Diego and will be published in the 2008 Proceedings of the American Association for Cancer Research. The ICA-1 compound has demonstrated more exacting specificity of protein kinase C-iota and not of proteins that are closely related to PKC-iota. These results...
Source: Cancer Weekly (2008-04-22)
|
